PD-L1 expression and prognostic impact in glioblastoma

BACKGROUND: Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Nduom, Edjah K., Wei, Jun, Yaghi, Nasser K., Huang, Neal, Kong, Ling-Yuan, Gabrusiewicz, Konrad, Ling, Xiaoyang, Zhou, Shouhao, Ivan, Cristina, Chen, Jie Qing, Burks, Jared K., Fuller, Greg N., Calin, George A., Conrad, Charles A., Creasy, Caitlin, Ritthipichai, Krit, Radvanyi, Laszlo, Heimberger, Amy B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2016
Schlagworte:
Basic and Translational Investigations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4724183/
https://ncbi.nlm.nih.gov/pubmed/26323609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov172
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge